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A B S T R A C T
The treatment of long and diffuse coronary lesions with percutaneous coronary 
intervention (PCI) has been problematic. Since the era of plain balloon angioplasty, 
lesion length has been a factor related to higher rates of restenosis and target lesion 
revascularization (TLR). With the advent of bare-metal stents, long and multiple stents 
were used to completely cover the diseased segments in order to improve outcomes. 
It has been shown that stenting of long coronary lesions (>20 mm) is related to sig-
nificantly higher rates of TLR than more discrete lesions and lesion length remained 
an independent risk factor for restenosis. The risk was further increased by the mul-
tiplicity of implanted stents. Full-cover stenting of long lesions is likely to give rise to 
diffuse, malignant in-stent restenosis which may necessitate multiple additional PCI 
procedures and often bypass surgery. Thus, covering the lesion with the least number 
of non-overlapping stents might reduce the risks of restenosis. This strategy, called 
spot stenting, was described by Colombo and colleagues to treat discrete high-grade 
disease within moderately diseased vessels. It consists of implantation of short stents 
only in discrete tightest segments of a long lesion and has been shown to significantly 
reduce restenosis rates.
Drug-eluting stents (DES) have been consistently shown to reduce restenosis and 
the need for TLR and thus provide improved clinical efficacy compared with bare 
metal stents. In current practice interventionalists implant DES to cover the entire 
atherosclerotic lesion and the stented length tends to be longer than the lesion length. 
However, even with DES diffuse disease and long lesions are still associated with an 
increased risk of restenosis, need for TLR and major adverse cardiac events (MACE). 
A major long-term concern regarding DES is the potential for stent thrombosis. The 
SYNTAX trial showed a stent thrombosis rate of 3.3% at 1 year which suggests that 
complex procedures with implantation of longer and multiple stents to treat multi-vessel 
disease and fully cover atherosclerotic lesions may be associated with an increased risk 
for stent thrombosis. Overlapping of DES is also related to delayed arterial healing, 
inflammation persistence and malapposition which predispose to late DES thrombosis. 
Thus, covering long lesions with the least number of non-overlapping stents might be 
beneficial even when DES are used. Data are still limited, but recent reports suggest 
that when DES are used selective stenting of only the severely stenosed areas of long 
lesions reduces the risk of MACE compared to full lesion coverage.
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AbbreviAtions
DES = drug-eluting stent(s)
MACE = major adverse cardiac events
PCI = percutaneous coronary intervention
TLR = target lesion revascularization 
